Inoa | Kūleʻaam paleki i ka milo |
Ka helu helu | 224785-90-4 |
Mlecular noncula | C23h32N6O4s |
Kaupaona molebular | 488.6 |
Nā helu einecs | 607-08-5 |
Malting Point | 230-235 ° C |
Huakai | 1.37 |
Kūlana paʻa | I hoʻopaʻaʻia i loko o ka maloʻo, kūʻai ma FREETER, ma lalo o -20 ° C |
ʻAno | Pauku |
Kāleka | Keʻokeʻo |
Acidity chee | (PKA) 9.86 ± 0.20 (wānana) |
Vardenafil (kumuhana pili 5- (4-Ethylppipezin-1-yl-1-sulfonyl) phenyl-7-prosazno-3h-othyl-3h-3,2 VardenaFilydronfillorlorlorWarshrollworld%; VardenaFILYDROWCHOMRILROLLYDRAIRYTREARLTYDERSURYTRAHY CS # 224785-90-4FORRANLE; Hana i nā mea hana hana. ʻO Miyyl-4--oxo-7-proppolidazo [5,1-F *-Yol
Hana pharmacological
ʻO kēia lāʻau lapaʻau kahi phosphodierakeseese helu 5 (pde5) inhibitor. Hiki i ka hoʻokele kino o kēia lāʻau lapaʻau ke hoʻomaikaʻi maikaʻi i ka maikaʻi a me ka lōʻihi o keʻano o ke olaʻana i ke ola kāne i ke ola kāne kāne me nā mea maʻi kāne. ʻO ka hoʻomakaʻana a me ka mālamaʻana i ka hana o ka penikala e pili ana i ka hoʻomahaʻana o ka cevernosh collast Mālama kēia lāʻau lapaʻau i ka decomposition o CGMP i ka hoʻohālikelikeʻana i ka chosnotsum o ka cgpus, a me keʻano o ka penis. Hoʻohālikelike me Phosphodeeseseese isozsmes 1, 2, 3, a me 6, a me 6, a me 6, a me 6, a me 6, a me 6, a me 6, a me 6, a 6 Hōʻike kekahi mauʻikepili i kona kohoʻana a me ka hopena inhibitory ma luna o PhosphodieSteesesese Type phosphosesteree
Nā lāʻau lapaʻau a me nā noi
1 ʻO ka hypotensi, nā loli eʻike ai, ke poʻo, ke poʻo, fuclus flamuning, priapism). Pono e paleʻia kēia lāʻau lapaʻau i ka hui pū me RitionIr a me Indinavir. I ka wā e hui pū ai me Erythromycin,ʻo Ketoazole, a me ITraconzozle
2. E lawe ana nā poʻe maʻi i nā mea pono a iʻole ka loaʻaʻana o ka nitric oxide donor e pale i kēia lāʻau lapaʻau. ʻO keʻano o kāna hana o ka hana e hoʻonui hou i kaka hoʻohālikelikeʻana o CGMP, e hopena ana i ka hopena antihyperte i hoʻonuiʻia a hoʻonuiʻia ka naʻau naʻau. Ke hoʻohana pūʻia me nā blockers α-resptor, hiki iā ia ke hoʻonui i ka hopena Antihypertenson a alakaʻi i ka hypotension. No laila, ua pāpāʻia ka hoʻohanaʻana o kēia lāʻau lapaʻau no ka poʻe e hoʻohana ana i nā lawena Haʻawina noʻo ka hoʻohanaʻana i loko o ka poʻe lawe aku iā α-loaʻa nā blocker. ʻO kahi meaʻai momona-momona
Lakanana Hana
Ua hoʻopiliʻiaʻo ia ma hope o ka hoʻokele waha,ʻo ka biovatelabile o ka'āina o ka'āinaʻo 15%, a me ka manawa maʻamau ke nānā akuʻo 1h (0.5-2h). ʻO ka hopena o ka'āina he 10mg a 20mg paha,ʻo ka manawa kiʻekiʻeʻo 0.9h a me 0.7h, a me 21,2 ʻO ka uku o ka protein i loaʻa i kēia lāʻau lapaʻau e pili ana i ka 95%. 1.5th ma hope o kahiʻano o keʻano he 20 mg,ʻo kaʻikepili o ka lāʻau lapaʻau i loko o ka semen he 0.00018% o ka pā. ʻO ka lāʻau lapaʻau nui ka metabilin ma ka Lie e Cytochrome P450 ʻO ka metabolite nuiʻo M1 i hoʻokumuʻia e ka dethylation o keʻano o ka papezine o kēia lāʻau lapaʻau. ʻO M1 hoʻi ka hopena o ka hoʻopiliʻana i nā phoshodeteemake ai i ka 2 (e pili ana i 7% o ka hopena kiʻekiʻe), aʻo kona koko ke heluheluʻia ke koko. , a hiki ke lilo hou i ka metabolilized. Nā kumukūʻai excretion o nā lāʻau lapaʻau ma keʻano o nā metabolites i nā feces a me ka urine e pili ana iā 91% a me ka 95% a me ka 4% a me 2%. ʻO ka nui o ka hoʻomaʻemaʻe pihaʻana o ka nui, 50 l i hoʻokahi hola, a me nā hapa hapa o ka nui o ka makua makua a me nā hola he 5 a 5 paha.